Want to join the conversation?
In the US Branded business, $ENDP secured FDA approval for BELBUCA, continued to drive growth for XIAFLEX and supported OPANA ER. In US Generics, the company closed the acquisition of Par achieving critical mass. Within International, $ENDP closed the Aspen portfolio acquisition for Litha Group which is now refocused on pharmaceuticals.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?